Vistagen Therapeutics, Inc. Operating Income Loss

• Vistagen Therapeutics, Inc. showed a decrease of -69.5% in Operating Income Loss from 2024 to 2025.
• This data is from Vistagen Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 17, 2025.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2011 to 2025), Vistagen Therapeutics, Inc.'s Operating Income Loss has declined by 752.6%.
• Historical annual values: Fiscal year 2025: -$55.97 million | Fiscal year 2024: -$33.02 million | Fiscal year 2023: -$59.27 million | Fiscal year 2022: -$47.78 million | Fiscal year 2021: -$17.93 million | Fiscal year 2020: -$20.80 million | Fiscal year 2019: -$24.56 million | Fiscal year 2018: -$14.20 million | Fiscal year 2017: -$10.25 million | Fiscal year 2016: -$17.85 million | Fiscal year 2015: -$6.78 million | Fiscal year 2014: -$5.03 million | Fiscal year 2013: -$6.79 million | Fiscal year 2012: -$9.04 million | Fiscal year 2011: -$6.56 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026